# A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

> **NCT01874665** · PHASE2 · COMPLETED · sponsor: **Ariad Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- GIST

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT01874665
- **Lead sponsor:** Ariad Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-05
- **Primary completion:** 2015-02-28
- **Final completion:** 2016-07-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01874665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01874665, "A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01874665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*